UB Paderborn / Katalog / Suche / in CDI

1 – 18 von 18

Sortiert nach

Effect of a multipayer patient-centered medical home on health care utilization and quality: the Rhode Island chronic care sustainability initiative pilot program

JAMA internal medicine, 2013-11, Vol.173 (20), p.1907

2013

Link zum Volltext

Verfügbarkeit prüfen

Clonally unrelated primary large B‐cell lymphomas separated by over a decade involving the central nervous system and testicle: Possible predisposition to lymphomas of immune‐privileged sites?

EJHaem, 2024-06, Vol.5 (3), p.599-602

2024

Link zum Volltext

Verfügbarkeit prüfen

A Difference-in-Difference Analysis of Changes in Quality, Utilization and Cost Following the Colorado Multi-Payer Patient-Centered Medical Home Pilot

Journal of general internal medicine : JGIM, 2016-03, Vol.31 (3), p.289-296

2016

Link zum Volltext

Verfügbarkeit prüfen

Impact of the Cincinnati Aligning Forces for Quality Multi-Payer Patient Centered Medical Home Pilot on Health Care Quality, Utilization, and Costs

Medical care research and review, 2016-10, Vol.73 (5), p.532-545

2016

Link zum Volltext

Verfügbarkeit prüfen

1423 Novel immunotherapy based on commensal-derived peptides to drive an effective CD8 T Cell response against selected tumor-associated antigens (TAAs)

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A1582-A1582

2023

Link zum Volltext

Verfügbarkeit prüfen

A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas

British journal of haematology, 2009-06, Vol.145 (6), p.741-748

2009

Link zum Volltext

Verfügbarkeit prüfen

Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma

Blood advances, 2023-09, Vol.7 (17), p.5082-5090

2023

Link zum Volltext

Verfügbarkeit prüfen

Intraclonal Heterogeneity Caused By Activation-Induced Cytidine Deaminase Is Not a Prognostic Biomarker in Untreated Advanced Stage Follicular Lymphoma: An Analysis of SWOG S0016

Blood, 2019-11, Vol.134 (Supplement_1), p.2771-2771

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of a TLR‐9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma

British journal of haematology, 2009-08, Vol.146 (3), p.282-291

2009

Link zum Volltext

Verfügbarkeit prüfen

Subclonal Mutations of TP53 Are Common in Untreated Follicular Lymphoma and Mutation Status Is Predictive of PFS When CHOP Is Combined with 131-Iodine Tositumomab but Not with Rituximab: An Analysis of SWOG S0016

Blood, 2018-11, Vol.132 (Supplement 1), p.919-919

2018

Link zum Volltext

Verfügbarkeit prüfen

Impact of the Cincinnati Aligning Forces for Quality Multi-Payer Patient Centered Medical

Medical care research and review, 2016-10, Vol.73 (5), p.532

2016

Link zum Volltext

Verfügbarkeit prüfen

THE INCIDENCE AND NATURAL HISTORY OF MITRAL REGURGITATION FOLLOWING SURGICAL REPAIR OF TOTAL ANOMALOUS PULMONARY VENOUS DRAINAGE

Journal of the American College of Cardiology, 2013-03, Vol.61 (10), p.E433-E433

2013

Link zum Volltext

Verfügbarkeit prüfen

The Peace Labyrinth: An Interactive Exhibition on Conflict Resolution

Curator (New York, N.Y.), 2012-07, Vol.55 (3), p.341-354

2012

Link zum Volltext

Verfügbarkeit prüfen

Bortezomib and Gemcitabine in Relapsed Hodgkin Lymphoma (HL)

Blood, 2007-11, Vol.110 (11), p.2325-2325

2007

Link zum Volltext

Verfügbarkeit prüfen

A Phase 2 Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas

Blood, 2007-11, Vol.110 (11), p.1358-1358

2007

Link zum Volltext

Verfügbarkeit prüfen

CpG Oligonucleotide (1018 ISS) May Overcome Rituximab (R) Resistance in Follicular Lymphoma (FL) through Enhanced ADCC, T Cell Expansion, and Alteration of Tumor Microenvironment

Blood, 2005-11, Vol.106 (11), p.2434-2434

2005

Link zum Volltext

Verfügbarkeit prüfen

1 – 18 von 18

Suche als RSS-Feed

Aktive Filter

Nur zeigenGeprüft (Peer-Review)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Mit Volltextzugriff
(16)

Publikationsform

Artikel
(18)

Sprache

Englisch
(18)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Effect of a multipayer patient-centered medical home on health care utilization and quality: the Rhode Island chronic care sustainability initiative pilot program

Clonally unrelated primary large B‐cell lymphomas separated by over a decade involving the central nervous system and testicle: Possible predisposition to lymphomas of immune‐privileged sites?

A Difference-in-Difference Analysis of Changes in Quality, Utilization and Cost Following the Colorado Multi-Payer Patient-Centered Medical Home Pilot

Impact of the Cincinnati Aligning Forces for Quality Multi-Payer Patient Centered Medical Home Pilot on Health Care Quality, Utilization, and Costs

1423 Novel immunotherapy based on commensal-derived peptides to drive an effective CD8 T Cell response against selected tumor-associated antigens (TAAs)

A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas

Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma

Intraclonal Heterogeneity Caused By Activation-Induced Cytidine Deaminase Is Not a Prognostic Biomarker in Untreated Advanced Stage Follicular Lymphoma: An Analysis of SWOG S0016

Phase II study of a TLR‐9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma

Subclonal Mutations of TP53 Are Common in Untreated Follicular Lymphoma and Mutation Status Is Predictive of PFS When CHOP Is Combined with 131-Iodine Tositumomab but Not with Rituximab: An Analysis of SWOG S0016

Impact of the Cincinnati Aligning Forces for Quality Multi-Payer Patient Centered Medical

THE INCIDENCE AND NATURAL HISTORY OF MITRAL REGURGITATION FOLLOWING SURGICAL REPAIR OF TOTAL ANOMALOUS PULMONARY VENOUS DRAINAGE

The Peace Labyrinth: An Interactive Exhibition on Conflict Resolution

Bortezomib and Gemcitabine in Relapsed Hodgkin Lymphoma (HL)

A Phase 2 Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas

Combination Immunotherapy with a CpG Oligonucleotide and Rituximab (R) Augments the Immunological Response and Favorably Alters the Malignant Microenvironment of Follicular Lymphoma (FL)

CpG Oligonucleotide (1018 ISS) May Overcome Rituximab (R) Resistance in Follicular Lymphoma (FL) through Enhanced ADCC, T Cell Expansion, and Alteration of Tumor Microenvironment

Most Influential Landscapes

Aktive Filter

Suchergebnisse filtern